TWST - Goldman Sachs Upgrades Twist Bioscience Says Express Genes Launch Will Drive Margin Expansion | Benzinga
Goldman Sachs has upgraded Twist Bioscience Corp (NASDAQ:TWST) looking forward to 2024 and beyond, and the analyst sees the critical new product launch of Express Genes directly addressing their gross margin issues within their SynBio division.
Historically, well-funded larger biopharma companies were challenging for TWST to penetrate due to extended gene delivery timelines.
However, with the introduction of Express Genes for new customers in 2024, TWST can now cater to these companies by delivering genes within 5-7 days, positioning Twist to tap into a previously inaccessible market and offering a unique growth opportunity to enhance revenue and profit margins.
Goldman analyst has upgraded the stock from Neutral to Buy.
The expedited delivery of Express Genes mitigates the risk associated ...